Cannabidiol - Botanix Pharmaceuticals

Drug Profile

Cannabidiol - Botanix Pharmaceuticals

Alternative Names: BTX 1204; BTX 1308; BTX 1503; BTX1204 - Atopic dermatitis; BTX1308 - Plaque psoriasis; BTX1503 - Acne; Cannabidiol transdermal gel - Botanix Pharmaceuticals

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Botanix Pharmaceuticals
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acne; Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 12 May 2017 Preclinical trials in Atopic dermatitis in Australia (Transdermal) before May 2017 (Botanix Pharmaceuticals pipeline, May 2017)
  • 12 May 2017 Preclinical trials in Plaque psoriasis in Australia (Transdermal) before May 2017 (Botanix Pharmaceuticals pipeline, May 2017)
  • 03 May 2017 Botanix Pharmaceuticals plans a phase I trial in healthy volunteers in Australia (ACTRN12617000642381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top